Evidence map›Paper›PMID 30526311›Full record

ArticlemAbs

Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice.

Andrew Kroetsch, Chunxia Qiao, Mairead Heavey, Leiming Guo, Dhaval K Shah, Sheldon Park

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. pH-responsive antibodies for therapeutic applications.Journal of biomedical science · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Andrew Kroetscha Department of Chemical and Biological Engineering , University at Buffalo , Buffalo , New York , USA.
Chunxia Qiaob Department of Pharmaceutical Sciences , University at Buffalo , Buffalo , New York , USA.
Mairead Heaveyb Department of Pharmaceutical Sciences , University at Buffalo , Buffalo , New York , USA.
Leiming Guob Department of Pharmaceutical Sciences , University at Buffalo , Buffalo , New York , USA.
Dhaval K Shahb Department of Pharmaceutical Sciences , University at Buffalo , Buffalo , New York , USA.
Sheldon Parka Department of Chemical and Biological Engineering , University at Buffalo , Buffalo , New York , USA.ORCID 0000-0002-3831-000X
University at Buffalo, State University of New York · US

Funding

Translational Systems Pharmacokinetic Models of Novel Anticancer BiologicsR01GM114179 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI SHAH, DHAVAL K · 2015 to 2019
$1.7M
Modulation of antigen pharmacokinetics with pH dependent antibodyR21AI138195 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PARK, SHELDON · 2018 to 2019
$425k
NIAID NIH HHS R21 AI138195NIGMS NIH HHS R01 GM114179
6 · The paper itself

Abstract

A new modality in antibody engineering has emerged in which the antigen affinity is designed to be pH dependent (PHD). In particular, combining high affinity binding at neutral pH with low affinity binding at acidic pH leads to a novel antibody that can more effectively neutralize the target antigen while avoiding antibody-mediated antigen accumulation. Here, we studied how the in vivo pharmacokinetics of the superantigen, Staphylococcal enterotoxin B (SEB), is affected by an engineered antibody with pH-dependent binding. PHD anti-SEB antibodies were engineered by introducing mutations into a high affinity anti-SEB antibody, 3E2, by rational design and directed evolution. Three antibody mutants engineered in the study have an affinity at pH 6.0 that is up to 68-fold weaker than the control antibody. The pH dependency of each mutant, measured as the pH-dependent affinity ratio (PAR - ratio of affinity at pH 7.4 and pH 6.0), ranged from 6.7-11.5 compared to 1.5 for the control antibody. The antibodies were characterized in mice by measuring their effects on the pharmacodynamics and pharmacokinetics (PK) of SEB after co-administration. All antibodies were effective in neutralizing the toxin and reducing the toxin-induced cytokine production. However, engineered PHD antibodies led to significantly faster elimination of the toxin from the circulation than wild type 3E2. The area under the curve computed from the SEB PK profile correlated well with the PAR value of antibody, indicating the importance of fine tuning the pH dependency of binding. These results suggest that a PHD recycling antibody may be useful to treat intoxication from a bacterial toxin by accelerating its clearance.

Indexed as

AnimalsAntibodies, MonoclonalAntibody AffinityEnterotoxinsHydrogen-Ion ConcentrationMiceProtein EngineeringSuperantigensAntibodies, Monoclonalenterotoxin B, staphylococcalEnterotoxinsSuperantigensantigen pharmacokineticsmonoclonal antibodypH-dependent antibodyStaphylococcal enterotoxin B

Identifiers

PMID30526311
PMCPMC6380392
OpenAlexW2905274775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.